Should you build or buy Molecular Modeling & Computational Drug Discovery?
Molecular modeling and computational drug discovery software simulates how small molecules bind to protein targets, using docking, molecular dynamics, free-energy calculations and structure prediction to prioritize which compounds to synthesize and test. Pharmaceutical and biotech discovery teams buy or build it to cut the number of physical assays a program needs.
Can we run discovery on RDKit, OpenMM, GROMACS and open models instead of licensing Schrödinger or MOE? Partly, and named teams do, but not as a wholesale replacement. The open stack is production-grade for screening, cheminformatics and custom ML, while validated FEP, force fields and GxP-ready workflows still favor a commercial licence. Buy the validated core, build selectively around it, and benchmark every open method against your own experimental data before trusting it in lead optimization.
Build it, buy it, or bridge?
When building makes sense
Named independent teams already run a meaningful share of computational drug discovery on open tools. VirtualFlow, a free and open-source screening platform published in Nature, has run ultra-large virtual screens against real targets on ordinary computing clusters. RDKit handles the cheminformatics that used to require a commercial toolkit, and OpenMM and GROMACS cover molecular dynamics that once justified a license on their own. Recursion and Insilico Medicine built in-house discovery platforms that carried candidate molecules into clinical trials, showing the model works past the prototype stage for a well-resourced biotech. What none of these builds replace outright is a validated free-energy engine like Schrodinger's FEP+, whose accuracy against real binding data has been benchmarked across large pharma programs for years, or the audit-ready workflow a regulated program needs. Build when your team has computational chemists who can validate open methods against your own assay results, and expect to keep licensing the free-energy core even then.
When buying makes sense
Buying the validated core is the right call for most discovery programs, and it does not mean giving up the open stack around it. Schrodinger's FEP+ is used across pharma and biotech for binding-affinity prediction with accuracy the company reports as approaching experimental methods, backed by drug candidates that reached the clinic on its predictions. MOE and BIOVIA Discovery Studio round out the commercial suites with integrated modeling environments a team can be productive in immediately, without assembling and validating a pipeline from open components first. The honest reason to buy is that a validated, supported free-energy engine took years of benchmarking against real experimental data to earn its accuracy, and reproducing that validation internally is a separate research project from running your actual discovery program. License the validated core for the calculations that decide which molecules get synthesized, and build the screening, cheminformatics and custom ML layers around it where your team already has real capability.
The desk read
Build-versus-buy analysis for Molecular Modeling & Computational Drug Discovery is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.
Frequently asked
Can a small biotech run discovery on open-source tools alone?
For screening and cheminformatics, largely yes. RDKit, OpenMM, GROMACS and platforms like VirtualFlow are production-grade and used in named academic and industry screens. Validated free-energy accuracy for lead optimization is the harder piece to replicate, which is why even computationally strong biotechs often keep a licensed engine for that specific step.
Do AI-native biotechs like Recursion actually replace vendor software?
They replace parts of it. Recursion and Insilico Medicine built in-house platforms covering screening, cheminformatics and custom machine learning that carried molecules into clinical trials. Neither company is documented as having retired every commercial modeling tool; the build sits alongside licensed software for specific validated calculations.
What's the actual difference between free energy perturbation and docking?
Docking predicts a likely binding pose quickly and cheaply, useful for screening large libraries. Free energy perturbation calculates binding strength with much higher computational cost and, when validated, much higher accuracy, which is why it is reserved for a shortlist of candidates rather than an initial screen of millions.
Is AlphaFold a substitute for a licensed modeling platform?
It solves a different problem. AlphaFold predicts protein structure, which feeds into modeling workflows, but its commercial-use terms are restricted and it does not replace docking, molecular dynamics or free-energy calculation. Most programs use structure predictions from tools like AlphaFold as an input to the modeling pipeline, not as a replacement for it.